Insulin degludec/insulin aspart
< Insulin degludec
| Combination of | |
|---|---|
| Insulin degludec | Long-acting human insulin analog |
| Insulin aspart | Fast-acting human insulin analog |
| Clinical data | |
| Trade names | Ryzodeg |
| AHFS/Drugs.com | Professional Drug Facts |
| Pregnancy category |
|
| Routes of administration | Subcutaneous injection |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| KEGG | |
Insulin degludec/insulin aspart, sold under the brand name Ryzodeg, is a fixed-dose combination medication for the treatment of diabetes mellitus. It contains insulin degludec and insulin aspart. It is given as an injection under the skin in the abdominal wall (at the front of the waist), upper arm or thigh.
The most frequently reported side effect is hypoglycemia (low blood glucose levels).
It was approved for medical use in the European Union in January 2013, and in Australia in November 2017.